After Hours Summary: AVAV +18.2% sharply higher on earnings; ABVX +23.4% on trial results; CNXC -22.2% under pressure after earnings
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: AVAV +18.2%
Companies trading higher in after hours in reaction to news: ABVX +23.4% (reports ABTECT maintenance Part 2 results for Obefazimod), CCOI +7% (closes on sale of 10 data center facilities), GMAB +2.2% (topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab and lenalidomide), DHT +1.8% (will implement a proactive design upgrade for its two newbuildings delivering from Hyundai this year), REGN +1.3% (FDA selects seven particpants for PreCheck Pilot Program), MX +1.1% (names new CEO), CMCSA +0.7% (NBCUniversal weighing potential video-game entry post split; cable and connectivity business eyes technology investments, according to Reuters), AMRX +0.6% (FDA selects seven particpants for PreCheck Pilot Program), MEOH +0.4% (provides update on Trinidad and Tobago operations), FSM +0.4% (results from the feasibility study for its Diamba Sud Gold Project in Senegal), AZO +0.2% (Trump Administration issues memos relating to automotive repairs)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: CNXC -22.2%
Companies trading lower in after hours in reaction to news: NVCT -18.1% (stock offering), MAMA -12.8% (stock offering), VSH -10.4% (stock offering), FPS -4.9% (stock offering; also stock offering by holders), DLR -2.4% (to purchase BX interest in three data centers; also secondary offering of common stock by BX), TLRY -0.4% (announces acquisition of HelloMD), ORLY -0.2% (Trump Administration issues memos relating to automotive repairs), LLY -0.1% (FDA selects seven particpants for PreCheck Pilot Program)